255
Participants
Start Date
December 31, 2010
Primary Completion Date
August 31, 2011
Study Completion Date
November 30, 2011
Placebo
Placebo vaginal suppository
DHEA
Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
DHEA
Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
EndoCeutics site # 19, New York
EndoCeutics site # 35, Pittsburgh
EndoCeutics site # 31, Charlottesville
EndoCeutics site # 03, Norfolk
EndoCeutics site # 16, Durham
EndoCeutics site # 23, Sandy Springs
EndoCeutics site # 26, Jacksonville
EndoCeutics site # 45, Boynton Beach
EndoCeutics site # 39, Montgomery
EndoCeutics site # 15, Columbus
EndoCeutics site # 05, Cleveland
EndoCeutics site # 22, Kalamazoo
EndoCeutics site # 25, Lincoln
EndoCeutics site # 36, Denver
EndoCeutics site # 10, Meridian
EndoCeutics site # 09, West Jordan
EndoCeutics site # 14, Tucson
EndoCeutics site # 30, San Diego
EndoCeutics site # 17, San Diego
EndoCeutics site # 21, Sacramento
EndoCeutics site # 42, Milford
EndoCeutics site # 27, Baltimore
EndoCeutics site # 28, Moorestown
EndoCeutics site # 44, New Brunswick
EndoCeutics site # 13, Calgary
EndoCeutics site # 06, Bathurst
EndoCeutics site # 04, Drummondville
EndoCeutics site # 12, Montreal
EndoCeutics site # 02, Québec
EndoCeutics site # 01, Québec
EndoCeutics site # 18, Saint Romuald
EndoCeutics site # 08, Shawinigan
EndoCeutics site # 11, Sherbrooke
Lead Sponsor
EndoCeutics Inc.
INDUSTRY